1. Volume 370, Issue 9605, Pages 2103-2111 (December 2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial 
Dr, Prof Bernard Escudier, MD, Prof Anna Pluzanska, MD, Piotr Koralewski, MD, Prof Alain Ravaud, MD, Prof Sergio Bracarda, MD, Prof Cezary Szczylik, MD, Christine Chevreau, MD, Marek Filipek, MD, Bohuslav Melichar, MD, Prof Emilio Bajetta, MD, Prof Vera Gorbunova, MD, Jacques-Olivier Bay, MD, Istvan Bodrogi, MD, Agnieszka Jagiello-Gruszfeld, MD, Nicola Moore, MSc 
The Lancet 
Volume 370, Issue 9605, Pages (December 2007)
DOI: /S (07)
Copyright © 2007 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival
Interim analysis of overall survival based on 251 of 450 scheduled events. Median overall survival had not been reached in the bevacizumab plus interferon alfa group. Final analysis of progression-free survival based on 505 progression events.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

4. Figure 3 Subgroup analysis of progression-free survival
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions